Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023

Rhea-AI Summary

Genelux Corporation will be participating in BTIG’s Virtual Biotechnology Conference 2023, where Thomas Zindrick, the President, CEO, and Chairman of the company, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat with Kaveri Pohlman, PhD, BTIG Biotechnology Analyst.

WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG’s Virtual Biotechnology Conference 2023.

The conversation with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst, is scheduled to begin at 4:00 p.m. ET on Tuesday, August 8, 2023.

About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux' discovery and development efforts revolves around the Company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.

Investor and Media Contacts

Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com 

Source: Genelux Corporation

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is Genelux Corporation.

What is the event where Genelux Corporation will be participating?

Genelux Corporation will be participating in BTIG’s Virtual Biotechnology Conference 2023.

Who will be discussing clinical-stage programs, recent announcements, and upcoming milestones?

Thomas Zindrick, the President, CEO, and Chairman of Genelux Corporation, will be discussing clinical-stage programs, recent announcements, and upcoming milestones.

Who will be conducting the fireside chat?

Kaveri Pohlman, PhD, BTIG Biotechnology Analyst, will be conducting the fireside chat.

When will the fireside chat take place?

The fireside chat is scheduled to begin at 4:00 p.m. ET on Tuesday, August 8, 2023.